# DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

> **NCT07472517** · PHASE3 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 670 (estimated)

## Conditions studied

- Small Cell Lung Cancer (SCLC)
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **DRUG:** obrixtamig
- **DRUG:** atezolizumab
- **DRUG:** carboplatin
- **DRUG:** etoposide

## Key facts

- **NCT ID:** NCT07472517
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-13
- **Primary completion:** 2028-09-09
- **Final completion:** 2029-07-30
- **Target enrollment:** 670 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07472517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07472517, "DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07472517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*